- Home
- TPVG vs NMRA Comparison
TPVG vs NMRA Comparison
Compare TPVG & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPVG
- NMRA
- Stock Information
- Founded
- TPVG 2013
- NMRA 2019
- Country
- TPVG United States
- NMRA United States
- Employees
- TPVG N/A
- NMRA N/A
- Industry
- TPVG Other Consumer Services
- NMRA
- Sector
- TPVG Consumer Discretionary
- NMRA
- Exchange
- TPVG Nasdaq
- NMRA Nasdaq
- Market Cap
- TPVG 273.2M
- NMRA 268.5M
- IPO Year
- TPVG N/A
- NMRA 2023
- Fundamental
- Price
- TPVG $6.35
- NMRA $1.65
- Analyst Decision
- TPVG Hold
- NMRA Buy
- Analyst Count
- TPVG 6
- NMRA 8
- Target Price
- TPVG $6.75
- NMRA $7.14
- AVG Volume (30 Days)
- TPVG 295.5K
- NMRA 2.2M
- Earning Date
- TPVG 08-06-2025
- NMRA 08-06-2025
- Dividend Yield
- TPVG 18.96%
- NMRA N/A
- EPS Growth
- TPVG N/A
- NMRA N/A
- EPS
- TPVG 1.03
- NMRA N/A
- Revenue
- TPVG $97,557,000.00
- NMRA N/A
- Revenue This Year
- TPVG N/A
- NMRA N/A
- Revenue Next Year
- TPVG $6.30
- NMRA N/A
- P/E Ratio
- TPVG $6.14
- NMRA N/A
- Revenue Growth
- TPVG N/A
- NMRA N/A
- 52 Week Low
- TPVG $5.53
- NMRA $0.61
- 52 Week High
- TPVG $8.50
- NMRA $17.19
- Technical
- Relative Strength Index (RSI)
- TPVG 29.01
- NMRA 51.99
- Support Level
- TPVG $7.15
- NMRA $1.54
- Resistance Level
- TPVG $6.97
- NMRA $2.85
- Average True Range (ATR)
- TPVG 0.19
- NMRA 0.26
- MACD
- TPVG -0.07
- NMRA -0.08
- Stochastic Oscillator
- TPVG 4.01
- NMRA 10.11
About TPVG TriplePoint Venture Growth BDC Corp.
TriplePoint Venture Growth BDC Corp is a closed-end, non-diversified management investment company. Its investment objective is to maximize its total return to stockholders in the form of current income and, to a lesser extent, capital appreciation. The fund focuses on companies operating in the fields of biofuels, business applications software, wireless communications equipment, e-commerce, clothing and accessories, conferencing equipment and services, personal goods, financial institutions and services, entertainment, mixed retailing, and healthcare services. Geographically, all the operations of the firm function through the region of the United states.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.